CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Sep. 26, 2015	Sep. 27, 2014
Cash Flows from Operating Activities:
Net income	$ 12,596	$ 3,839
Non-cash items:
Depreciation and amortization	44,998	41,625
Amortization of financing costs	435	572
Stock compensation expense	3,883	6,938
Loss on sale of property, plant and equipment	139	364
Unrealized (gain)/loss from hedging activities	(710)	554
Change in fair value of contingent consideration	171	459
Asset write-down	88	474
Change in operating assets and liabilities:
Change in accounts receivable, net	243	10,145
Change in inventories	2,510	(13,185)
Change in prepaid income taxes	(182)	(2,028)
Change in other assets and other liabilities	(1,712)	(8,160)
Tax benefit of exercise of stock options	1,375	854
Change in accounts payable and accrued expenses	(27,073)	2,529
Net cash provided by operating activities	36,761	44,980
Cash Flows from Investing Activities:
Capital expenditures	(50,130)	(70,872)
Proceeds from sale of property, plant and equipment	293	377
Other acquisitions and investments	3,000	0
Net cash used in investing activities	(52,837)	(70,495)
Cash Flows from Financing Activities:
Payments on long-term real estate mortgage	(558)	(513)
Net increase in short-term loans	6,924	786
Repayment of term loan borrowings	0	(8,531)
Proceeds from employee stock purchase plan	2,263	2,530
Proceeds from exercise of stock options	8,374	4,042
Share repurchases	(60,984)	(33,770)
Net cash used in financing activities	(43,981)	(35,456)
Effect of exchange rates on cash and cash equivalents	(358)	(1,527)
Net Change in Cash and Cash Equivalents	(60,415)	(62,498)
Cash and Cash Equivalents at Beginning of Period	160,662	192,469
Cash and Cash Equivalents at End of Period	100,247	129,971
Supplemental Disclosures of Cash Flow Information:
Interest paid	4,162	4,180
Income taxes paid	4,656	8,351
Transfers from inventory to fixed assets for placement of Haemonetics equipment	$ 5,550	$ 4,026